In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity

In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity,... Int Urol Nephrol (2017) 49:1691–1697 DOI 10.1007/s11255-017-1615-x NEPHROLOGY – ORIGINAL PAPER In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity 1 1 1 Theodoros Eleftheriadis · Georgios Pissas · Maria Sounidaki · 1 2 1 Georgia Antoniadi · Nikolaos Antoniadis · Vassilios Liakopoulos · Ioannis Stefanidis Received: 12 March 2017 / Accepted: 9 May 2017 / Published online: 15 May 2017 © Springer Science+Business Media Dordrecht 2017 Abstract Results In two-way MLRs, tacrolimus inhibited cell prolif- Purpose Acute cellular rejection is the major cause of eration more than everolimus. In one-way MLRs, tacroli- immune-mediated graft failure early in the course of kid- mus and everolimus decreased alloantibody production to ney transplantation, whereas chronic antibody-mediated the same extent. rejection is a major contributor to graft loss in the late post- Conclusions In human cell cultures, everolimus is infe- transplant phase. Based mainly on the results of short-term rior to tacrolimus in inhibiting cellular alloimmunity, but studies, the calcineurin inhibitor tacrolimus prevails over equally effective as regards humoral alloimmunity. Thus, the mammalian target of rapamycin (mTOR) inhibitors. everolimus might be a safe alternative in case of tacroli- However, the toxicity http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Urology and Nephrology Springer Journals

In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity

Loading next page...
 
/lp/springer_journal/in-human-cell-cultures-everolimus-is-inferior-to-tacrolimus-in-HUY50MLcfY
Publisher
Springer Netherlands
Copyright
Copyright © 2017 by Springer Science+Business Media Dordrecht
Subject
Medicine & Public Health; Nephrology; Urology
ISSN
0301-1623
eISSN
1573-2584
D.O.I.
10.1007/s11255-017-1615-x
Publisher site
See Article on Publisher Site

Abstract

Int Urol Nephrol (2017) 49:1691–1697 DOI 10.1007/s11255-017-1615-x NEPHROLOGY – ORIGINAL PAPER In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity 1 1 1 Theodoros Eleftheriadis · Georgios Pissas · Maria Sounidaki · 1 2 1 Georgia Antoniadi · Nikolaos Antoniadis · Vassilios Liakopoulos · Ioannis Stefanidis Received: 12 March 2017 / Accepted: 9 May 2017 / Published online: 15 May 2017 © Springer Science+Business Media Dordrecht 2017 Abstract Results In two-way MLRs, tacrolimus inhibited cell prolif- Purpose Acute cellular rejection is the major cause of eration more than everolimus. In one-way MLRs, tacroli- immune-mediated graft failure early in the course of kid- mus and everolimus decreased alloantibody production to ney transplantation, whereas chronic antibody-mediated the same extent. rejection is a major contributor to graft loss in the late post- Conclusions In human cell cultures, everolimus is infe- transplant phase. Based mainly on the results of short-term rior to tacrolimus in inhibiting cellular alloimmunity, but studies, the calcineurin inhibitor tacrolimus prevails over equally effective as regards humoral alloimmunity. Thus, the mammalian target of rapamycin (mTOR) inhibitors. everolimus might be a safe alternative in case of tacroli- However, the toxicity

Journal

International Urology and NephrologySpringer Journals

Published: May 15, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off